source
- Kolon TissueGene cuts 37 jobs after phase 3 osteoarthritis trial failsKolon TissueGene announced it will lay off 37 employees at its Maryland headquarters, with the reductions set to take effect at the end of August. The cuts follow a phase 3 trial of the company’s…
- FDA releases discussion paper seeking input on regulation of generative AI medical devicesThe U.S. Food and Drug Administration issued a discussion paper outlining considerations for regulating generative AI-enabled medical devices and asked stakeholders to provide feedback. The paper…